Allele Percentage of theBRAFV600E Mutation in Papillary Thyroid Carcinomas and Corresponding Lymph Node Metastases: No Evidence for a Role in Tumor Progression | Zendy

Greta Gandolfi | Zendy; Valentina Sancisi | Zendy; Federica Torricelli | Zendy; Moira Ragazzi | Zendy; Andrea Frasoldati | Zendy; Simonetta Piana | Zendy; Alessia Ciarrocchi | Zendy

Open Access

Allele Percentage of theBRAFV600E Mutation in Papillary Thyroid Carcinomas and Corresponding Lymph Node Metastases: No Evidence for a Role in Tumor Progression

Author(s) -

Greta Gandolfi,

Valentina Sancisi,

Federica Torricelli,

Moira Ragazzi,

Andrea Frasoldati,

Simonetta Piana,

Alessia Ciarrocchi

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-3930

Subject(s) - v600e , mutation , thyroid carcinoma , lymph node , allele , cancer research , thyroid cancer , biology , oncology , allele frequency , primary tumor , medicine , thyroid , cancer , pathology , gene , genetics , metastasis

The relevance of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) as a negative prognostic factor is a subject of intense debate. This mutation has been associated with several clinicopathological features, but the lack of consistency among data does not support its usefulness as marker of tumor aggressiveness and poorer outcome. Due to the genetic heterogeneity of the tumor, both the occurrence and the allele percentage of the BRAF mutation should be considered to unravel this controversy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research